Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases

Luis Rodríguez Padial1, Gonzalo Barón-Esquivias2, Antonio Hernández Madrid3

  • 1Department of Cardiology, Complejo Hospitalario de Toledo, Toledo, Spain. lrpadial@gmail.com.

Cardiology and Therapy
|March 27, 2016
PubMed

Insights

Diltiazem, a calcium channel blocker, effectively treats hypertension and related cardiovascular conditions like angina and atrial fibrillation. This review highlights its safety and efficacy, offering clinical practice recommendations.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVDs) are a leading global cause of mortality.
  • Hypertension is a major risk factor for CVDs, necessitating effective blood pressure control.
  • Calcium channel blockers are recognized as first-line agents for hypertension management.

Purpose of the Study:

  • To review the effectiveness and safety of diltiazem in treating various cardiovascular diseases.
  • To provide evidence-based recommendations for clinical diltiazem management.

Main Methods:

  • Review of clinical studies on diltiazem.
  • Expert analysis of diltiazem's efficacy and safety profile.
  • Evidence-based recommendation formulation.

Main Results:

  • Diltiazem is an effective and safe antihypertensive agent, used alone or in combination.
  • It reduces myocardial oxygen demand by lowering heart rate, blood pressure, and cardiac contractility, benefiting stable chronic angina.
  • Diltiazem slows atrioventricular node conduction, aiding heart rate control in atrial fibrillation.

Conclusions:

  • Diltiazem is a valuable therapeutic option for hypertension, stable chronic angina, and atrial fibrillation.
  • Clinical experts provide recommendations for optimal diltiazem use in practice.
  • Evidence supports diltiazem's role in managing key cardiovascular disorders.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
740
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
615